1. Home
  2. SIND vs MPLT Comparison

SIND vs MPLT Comparison

Compare SIND & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SIND

Sinda Ltd.

N/A

Current Price

$16.20

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$12.28

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIND
MPLT
Founded
N/A
2018
Country
United States
Employees
N/A
133
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SIND
MPLT
Price
$16.20
$12.28
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
99.9K
1.4M
Earning Date
N/A
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.03
$9.10
52 Week High
$16.37
$40.43

Technical Indicators

Market Signals
Indicator
SIND
MPLT
Relative Strength Index (RSI) 70.47 28.72
Support Level $11.88 $11.56
Resistance Level N/A $20.73
Average True Range (ATR) 1.44 2.03
MACD 0.28 -1.11
Stochastic Oscillator 93.98 11.12

Price Performance

Historical Comparison
SIND
MPLT

About SIND Sinda Ltd.

Sinda Ltd is an exploration stage company focused on acquiring, exploring, and developing mineral concessions in Mexico. The company holds mining concessions and exploration and exploitation rights for a silver-gold project located in the Guanajuato silver belt of Mexico. Its principal asset is the Sinda Property, a silver project at the exploration stage.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: